Generative AI in Regulatory Operations for Medical Devices: Use Cases, Tools, and Compliance Guardrails in 2026

The State of GenAI in Medical Device Regulatory Affairs

Generative AI has moved from experimentation to operational deployment in medical device regulatory affairs. The global regulatory technology (RegTech) market is projected at $17.5 billion in 2026 and is expected to reach $51.7 billion by 2032, reflecting a compound annual growth rate of approximately 19.5% (Research and Markets, January 2026). Industry surveys indicate that adoption of AI-powered compliance tools is accelerating across regulated industries, with the healthcare and pharmaceutical sectors increasingly deploying AI for regulatory intelligence, submission management, and quality system automation.

The driver is straightforward: regulatory affairs teams face increasing documentation volumes, tightening submission deadlines, and expanding global requirements — without proportional increases in headcount. Generative AI addresses this gap not by replacing regulatory professionals, but by eliminating the manual preparation work that consumes the majority of their time. Literature searches that took weeks can be completed in hours. First drafts of clinical evaluation sections that required days can be generated in minutes. Regulatory change monitoring that depended on manual scanning can be automated across 120+ markets simultaneously.

This guide covers where generative AI is delivering measurable value in medical device regulatory operations today, what the regulatory agencies say about using AI in submissions, and how to implement AI tools without violating GxP requirements.

High-Impact Use Cases

1. Regulatory Submission Drafting and Review

The most widely adopted GenAI use case in regulatory affairs is accelerating the preparation of submission documents. This includes:

• 510(k) and PMA documentation: AI tools draft device descriptions, substantial equivalence rationales, predicate device comparisons, and indications for use statements. Microsoft's eSTARHelper app integrates a GPT-4 copilot with the FDA's eSTAR template and domain-specific databases.
• CTD/eCTD module population: AI systems pre-populate common technical document modules using existing design history files, clinical study reports, and device master records. Gap analysis against eCTD structure requirements identifies missing sections before submission.
• Consistency checking: AI cross-references data across submission modules to identify discrepancies between the device description in one section and the risk analysis in another, or between clinical endpoints in the study report and the indications claimed in the labeling.
• Formatting and reference verification: Automated validation of reference formatting, citation completeness, and cross-link accuracy across multi-hundred-page submissions.

The critical caveat: FDA's 2025 draft guidance on AI in drug and device development makes clear that AI-generated content must be treated as a draft requiring full expert review. AI outputs are not GxP records. Every section of a regulatory submission that incorporates AI-generated text must be reviewed, verified, and approved by qualified personnel before submission. The AI accelerates the first draft; it does not replace human accountability.

2. Clinical Evaluation and Literature Review

Clinical evaluation is one of the most time-intensive regulatory activities, and GenAI is transforming several stages of the process:

• Systematic literature search: AI tools can search PubMed, Cochrane, Embase, and other databases using structured queries, screening thousands of abstracts for relevance in minutes rather than weeks.
• Appraisal and data extraction: AI models extract key data points (study design, sample size, endpoints, outcomes, adverse events) from selected full-text articles, populating literature review tables automatically.
• Clinical evaluation report drafting: Platforms like Celegence's CAPTIS use AI-powered authoring to generate CER sections aligned with MDR Article 61 requirements and MEDDEV 2.7/1 Rev. 4 methodology.
• Equivalence assessment: AI analyzes whether a proposed predicate device is technically, biologically, and clinically equivalent by comparing materials, intended use, and clinical data across device families.
• State-of-the-art review: AI synthesizes current clinical practice guidelines, published outcomes data, and competing device specifications to establish the state of the art for a given device category.

In 2026, several medical writing platforms have demonstrated measurable improvements: Celegence reports that its CAPTIS platform reduces time spent on non-analysis tasks in literature reviews by 62% (overall literature review time reduced by 28%), according to their published time-saving study. Deep Intelligent Pharma (DIP) reports over 99% accuracy for its AI-powered regulatory translation services, supporting multilingual global submissions.

3. Regulatory Intelligence and Change Monitoring

Regulatory intelligence — tracking changes in regulations, guidance documents, and standards across global markets — is essential but resource-intensive. AI tools now automate much of this function:

• Real-time monitoring: Platforms like RegDesk, Freyr RegIntel, and Centraleyes track regulatory updates across 120+ markets, automatically alerting teams to changes relevant to their device portfolios.
• Impact assessment: AI classifies regulatory changes by relevance and severity, mapping new requirements to existing internal policies and identifying gaps that need action.
• Document comparison: AI compares regulatory documents across jurisdictions to identify differences in requirements, helping teams preparing multi-market submissions understand where harmonized approaches are possible and where country-specific adaptations are needed.
• Predictive analytics: Some tools analyze historical regulatory trends to predict likely future changes, allowing proactive preparation rather than reactive scrambling.

The demand for AI-powered regulatory intelligence is growing rapidly across the life sciences sector, driven by the increasing complexity and volume of global regulatory changes that manufacturers must track and respond to.

4. Quality System Documentation and CAPA Management

GenAI is increasingly used to support quality management system operations:

• Deviation classification: AI tools automatically categorize incoming deviations by type and severity, routing them to appropriate investigation teams.
• Root cause analysis assistance: AI suggests probable root causes based on historical patterns in the deviation database, accelerating the investigation phase.
• CAPA drafting: AI generates initial CAPA documentation templates, including investigation summaries, corrective action plans, and effectiveness check criteria.
• Audit preparation: AI compiles and organizes quality records for internal and external audits, flagging potential findings before auditors find them.
• SOP drafting and revision: AI generates first drafts of standard operating procedures based on regulatory requirements and existing process descriptions.

5. Submission Quality Assurance

Before a submission reaches the regulatory agency, AI tools perform pre-submission quality checks:

• Completeness verification: Checking that all required sections are present and populated, aligned with the target agency's checklist (e.g., FDA eSTAR, EU MDR technical file requirements).
• Consistency analysis: Cross-referencing claims, data, and terminology across all submission documents to ensure no contradictions exist.
• Regulatory alignment: Comparing submission content against current agency guidance documents and standards to identify potential concerns before submission.
• Predictive deficiency assessment: Some tools analyze patterns in agency deficiency letters to predict likely questions or concerns, allowing sponsors to proactively address them.

What FDA and Other Agencies Say About AI in Regulatory Work

FDA Position

The FDA has not issued a final rule specifically governing the use of AI in preparing regulatory submissions, but several guidance documents and policy statements establish the agency's expectations:

• FDA 2025 draft guidance on AI in drug and device development: The guidance emphasizes that organizations must maintain human oversight and document AI tool use within their quality systems. AI-generated submission content is considered a draft requiring full expert review. AI tools used in regulated workflows should be addressed in Computer System Validation (CSV) documentation.
• Good Machine Learning Practice (GMLP) principles: While focused on AI/ML as a device function rather than AI as a workflow tool, the GMLP principles reinforce the FDA's expectation that AI-related activities be governed by the quality management system.
• FY 2026 guidance agenda: Includes planned guidance on AI-enabled device software, data governance, and lifecycle management, which will further define expectations for AI use in regulatory processes.

The practical implication: medical device companies using GenAI in regulatory operations must treat AI tools as part of their quality system infrastructure. This means validating the tools (or their outputs), documenting their use, maintaining audit trails, and ensuring that qualified personnel review all AI-generated content before it is included in any regulatory submission.

EU Perspective

The EU AI Act (Regulation 2024/1689), with its first major compliance deadline in August 2026, classifies AI systems embedded in medical devices as high-risk. While the AI Act primarily governs AI as a product feature rather than AI as a workflow tool, the data governance requirements in the AI Act overlap with GDPR and MDR obligations. Manufacturers using AI tools in their regulatory operations should:

• Conduct Data Protection Impact Assessments (DPIAs) that cover AI tool usage
• Document how AI-generated content is reviewed, verified, and approved
• Ensure AI tool vendors comply with GDPR data processing requirements
• Maintain records of AI tool use in regulated activities for audit purposes

ICH and International Harmonization

ICH has published reflection papers on AI use in clinical trials and regulatory submissions, signaling that formal guidance is forthcoming. Organizations should monitor ICH E6(R3) updates, which will address electronic records and AI-assisted processes in clinical trials.

Implementation Framework

Step 1: Inventory and Assess AI Use Cases

Before implementing any AI tool, map your regulatory operations to identify where AI can deliver the most value. Prioritize use cases based on:

• Volume of repetitive work: Literature review, first-draft generation, and formatting are high-volume, low-judgment tasks well-suited to AI.
• Error-prone processes: Consistency checking and completeness verification benefit from AI's ability to detect patterns and anomalies.
• Bottleneck activities: Identify which regulatory activities most frequently cause submission delays and assess whether AI can accelerate them.

Step 2: Select and Validate AI Tools

Evaluate AI tools against these criteria:

For tools used in GxP activities, follow your organization's computer system validation procedures (or the CSA framework if transitioning from CSV).

Step 3: Establish Governance

Implement a governance framework that addresses:

• AI use policy: Define which regulatory activities may use AI assistance and which require fully manual processes. For example, literature search assistance may be AI-permitted, while final clinical evaluation conclusions must be human-authored.
• Review and approval procedures: Every AI-generated output must be reviewed by a qualified regulatory professional before inclusion in any regulated document. Document who reviewed, when, and what changes were made.
• Audit trail requirements: Maintain records of AI tool usage, including prompts, outputs, reviewer comments, and final approved versions.
• Training: Regulatory, quality, and clinical teams must be trained on AI tool capabilities, limitations, and the organization's AI use policy. Training should cover prompt engineering basics, output verification techniques, and when to escalate AI limitations.
• Vendor management: Include AI tool vendors in the supplier quality management process. Assess their data handling practices, security controls, and change management procedures.

Step 4: Pilot, Measure, and Scale

Start with a pilot program focused on a single, well-defined use case — such as literature screening for CER updates or first-draft generation of 510(k) device descriptions. Measure:

• Time savings compared to manual processes
• Accuracy of AI outputs compared to expert-produced work
• Reviewer effort required to correct AI-generated content
• User satisfaction and adoption barriers

Use pilot results to refine prompts, review procedures, and governance controls before scaling to additional use cases.

Tools and Platforms in 2026

The market for AI-powered regulatory tools has matured significantly. Key categories include:

Regulatory Intelligence Platforms

• RegDesk: AI-powered tracking of regulatory updates across 120+ markets, automated impact assessment, submission management
• Freyr RegIntel: AI-driven regulatory intelligence for life sciences, change monitoring, and document comparison
• Centraleyes: Unified compliance platform with AI-assisted risk mapping, policy drafting, and vendor assessment

Clinical Evaluation and Medical Writing

• Celegence CAPTIS: AI-powered CER authoring platform aligned with MDR and IVDR requirements
• Deep Intelligent Pharma (DIP): Multi-agent AI authoring for clinical and regulatory content with enterprise-grade compliance and traceability
• DistillerSR: AI-assisted systematic literature review platform for clinical evaluations

Submission Preparation

• Microsoft eSTARHelper: GPT-4 copilot integrated with the FDA's eSTAR submission template
• Ketryx: AI-supported software lifecycle management and regulatory submission for SaMD
• Veeva Vault RIM: Regulatory information management with AI-enhanced submission tracking and document generation

General-Purpose AI Tools

Many regulatory teams also use general-purpose LLMs (GPT-4, Claude, Gemini) with custom prompts for specific tasks such as drafting regulatory correspondence, summarizing guidance documents, or generating first-pass translations of regulatory documents. When using general-purpose tools, extra care must be taken to ensure that proprietary data is not exposed to model training or third parties.

Risks and Limitations

Hallucination and Factual Accuracy

Generative AI models can produce plausible-sounding but factually incorrect content. In a regulatory context, this is dangerous — a fabricated clinical reference or an incorrect regulatory citation can undermine an entire submission. Every AI-generated factual claim must be verified against primary sources.

Confidentiality and Data Security

Inputting proprietary device data, clinical trial results, or submission content into a third-party AI platform may expose confidential information. Ensure that AI tools used for regulatory work provide enterprise-grade data isolation, do not use customer data for model training, and comply with GDPR and other applicable data protection regulations.

Over-Reliance and Skill Atrophy

Teams that routinely accept AI-generated first drafts without critical review risk losing the deep analytical skills that regulatory professionals bring to submissions. AI should augment human expertise, not replace it. Maintain a culture where AI outputs are treated as inputs to expert judgment, not final products.

Regulatory Acceptance

While regulatory agencies have not prohibited the use of AI in preparing submissions, they have made clear that the submitting organization bears full responsibility for the accuracy and completeness of all submission content, regardless of how it was generated. A poorly reviewed AI-generated submission will be judged no differently than a poorly prepared manual one — except that the submitting organization may face additional scrutiny if its AI governance is found inadequate.

The Future: Where GenAI in Regulatory Affairs Is Heading

Near-Term (2026–2027)

• Multimodal AI: Tools that process text, images, and data simultaneously for holistic submission review
• Predictive submission analytics: AI that predicts likely regulatory questions and deficiency items based on submission content and historical agency behavior
• Automated regulatory pathway selection: AI that analyzes device characteristics and recommends optimal regulatory pathways across jurisdictions

Medium-Term (2027–2029)

• Self-driving submissions: With human oversight, AI systems that manage end-to-end compilation of submission modules from design history files and clinical databases
• Real-time regulatory change integration: AI that automatically updates draft submissions in response to newly published guidance or standards changes
• Explainable AI (XAI) for regulatory: AI tools that provide transparent, auditable explanations of their outputs, enabling regulators to understand how AI-assisted content was generated

Long-Term (2029+)

• Autonomous regulatory lifecycle management: AI systems that manage the entire product regulatory lifecycle from pre-submission through post-market, flagging required updates, generating renewal documentation, and coordinating across global markets

Frequently Asked Questions

Can AI write my entire 510(k) submission? No. AI can generate first drafts of many sections, but every section requires expert review, fact-checking, and approval. AI accelerates the process but does not replace the qualified regulatory professional who takes responsibility for the submission's accuracy and completeness.

Does FDA require me to disclose that I used AI in preparing my submission? As of 2026, FDA has not issued a requirement to disclose AI use in submission preparation. However, the agency's guidance on AI in drug and device development emphasizes that AI tool use must be documented within the sponsor's quality system and that AI outputs must be validated by qualified personnel.

Do I need to validate AI tools used in regulatory operations? If the AI tool is used in a GxP activity (such as generating content for a regulatory submission or managing quality records), it should be addressed in your computer system validation documentation. The level of validation depends on how the tool is used and the risk of its output affecting product quality or patient safety.

Is it safe to input proprietary device data into AI tools? Only if the tool provides enterprise-grade data isolation and contractually commits to not using your data for model training. Review vendor data handling practices carefully before inputting any proprietary information. For highly sensitive data, consider using on-premise or private cloud deployments.

Will regulatory agencies accept AI-generated clinical evaluations? Agencies evaluate the content of submissions based on their scientific and regulatory merit, not on how they were produced. An AI-assisted clinical evaluation that is accurate, well-referenced, and meets the applicable regulatory requirements will be accepted. One that contains errors, unsupported claims, or fabricated references will be rejected — regardless of whether a human or an AI produced it.